Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zylox-Tonbridge Medical Technology Co's annualized ROCE % for the quarter that ended in Dec. 2025 was 7.20%.
Zylox-Tonbridge Medical Technology Co (FRA:818) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Zylox-Tonbridge Medical Technology Co ROCE % Related Terms
Zylox-Tonbridge Medical Technology Co ROCE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zylox-Tonbridge Medical Technology Co ROCE % Chart
(1) Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zylox-Tonbridge Medical Technology Co (FRA:818) has a ROCE % of 7.20% as of Dec. 2025.
Is Zylox-Tonbridge Medical Technology Co's ROCE % too high?
Zylox-Tonbridge Medical Technology Co's current ROCE % is 7.20%. The Medical Devices & Instruments industry median ROCE % is 2.93. Zylox-Tonbridge Medical Technology Co's value of 7.20% is 145.7% above this industry median. Overall, Zylox-Tonbridge Medical Technology Co has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zylox-Tonbridge Medical Technology Co's ROCE % compare to ABT and SYK?
Zylox-Tonbridge Medical Technology Co's ROCE % of 7.20% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.93. Zylox-Tonbridge Medical Technology Co's value of 7.20% is 145.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.93, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zylox-Tonbridge Medical Technology Co's current ROCE % of 7.20% is 145.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zylox-Tonbridge Medical Technology Co's current ROCE % is 7.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zylox-Tonbridge Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co (FRA:818) is currently considered Significantly Undervalued. The stock's GF Value™ is €3.72, compared to a current price of €2.08 — trading 44.1% below its estimated fair value. The current ROCE % is 7.20% and 145.7% above the Medical Devices & Instruments industry median of 2.93. Zylox-Tonbridge Medical Technology Co's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Zylox-Tonbridge Medical Technology Co (FRA:818), the current ROCE % is 7.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zylox-Tonbridge Medical Technology Co (FRA:818) Overvalued in 2026?
Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co stock appears to be undervalued.
The current stock price of €2.08 is trading 44.1% below its estimated GF Value™ of €3.72.
GuruFocus considers Zylox-Tonbridge Medical Technology Co to be Significantly Undervalued.
Key valuation signals for FRA:818:
ROCE %: 7.20%
GF Value™: €3.72 vs. price of €2.08 (44.1% below fair value)
Industry Position: 145.7% above the Medical Devices & Instruments median
No single metric tells the full story. See the FRA:818 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's products include Thrombite Clot Retriever Device (Thrombite CRD), Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB), and others. The company derives majority of its revenue from PRC.
76GF Score
Get the complete analysis for FRA:818
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:818 has been successfully added to your 
